Creating a model to treat pancreatic cancers with BRCA1/2 mutations
Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancers
This study is looking to create personalized treatment options for people with pancreatic cancer who have BRCA1/2 mutations, by testing different therapies to find the best ones that work for each individual.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10689186 on NIH RePORTER |
What this research studies
This research focuses on developing a personalized treatment platform for patients with pancreatic cancer that have BRCA1/2 mutations. By utilizing patient-derived models, the study aims to identify effective therapeutic strategies that exploit the vulnerabilities of these mutations, particularly through DNA-damage response and repair mechanisms. The approach involves testing various treatments to find the most effective options for individual patients, potentially leading to more tailored and effective therapies. The research team consists of international experts dedicated to improving outcomes for this specific subset of pancreatic cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic adenocarcinoma who have BRCA1 or BRCA2 mutations.
Not a fit: Patients with pancreatic cancer who do not have BRCA1/2 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with BRCA1/2-mutant pancreatic cancers.
How similar studies have performed: Previous research has shown promising results in targeting BRCA1/2 mutations in other cancers, indicating potential success for this novel approach in pancreatic cancer.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Brody, Jonathan — Oregon Health & Science University
- Study coordinator: Brody, Jonathan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.